Transplanted brown-fat-like cells hold promise for obesity and diabetes
26 August 2020

Microscopic images of the various types of fat tissues developed in mice after transplantation. Top panels show the fat tissue's general morphology, and the bottom panels are the tissue sections stained with hUCP1 (red color), which is unique for brown fat cells. These images show that while the HUMBLE fat cells are morphologically similar to the white fat cells, they express the brown fat specific hUCP1 protein. Credit: Joslin Diabetes Center

Obesity is the main cause of type 2 diabetes and related chronic illnesses that together will kill more people around the globe this year than the COVID-19 coronavirus. Scientists at Joslin Diabetes Center have delivered a proof of concept for a novel cell-based therapy against this dangerous condition.

The potential therapy for obesity would transplant HUMBLE (human brown-like) fat cells, human white fat cells that have been genetically modified to become similar to heat-generating brown fat cells, says Yu-Hua Tseng, Ph.D., a Senior Investigator in Joslin's Section on Integrative Physiology and Metabolism.

Brown fat cells burn energy instead of storing energy as white fat cells do, says Tseng, senior author on a paper about the work in *Science* Translational Medicine. In the process, brown fat can lower excessive levels of glucose and lipids in the blood that are linked to metabolic diseases such as diabetes.

However, people who are overweight or obese tend to have less of this beneficial brown fat—a barrier that HUMBLE cells are designed to overcome, Tseng says.

She and her colleagues created the cells from human white fat cells in a progenitor stage (not yet fully developed into their final fat form). The investigators used a variant of the CRISPR-Cas9 genome editing system to boost expression of a gene called UCP1, which triggers white fat cell progenitors to develop into brown fat-like cells.

Transplanted into mice lacking an immune system, the HUMBLE progenitor cells developed into cells that functioned very much like the mice's own brown fat cells, says Tseng, who is also a professor of medicine at Harvard Medical School.

Her team compared transplants of these cells versus the original white fat cells in mice who were put on a high fat diet. Mice given the HUMBLE transplants displayed much greater sensitivity to insulin and ability to clear glucose from the blood (two key factors that are impaired in type 2 diabetes).

Additionally, the mice receiving HUMBLE transplants put on less weight than mice with transplanted white fat cells, remaining in the same range as animals who received brown fat cells.

Perhaps surprisingly, the Joslin scientists demonstrated that these benefits were mostly due to signals from the transplanted cells to endogenous (existing) brown fat cells in the mice. "Cells in different tissues communicate with each other," Tseng says. "In this case, we found that our transplanted HUMBLE cells secrete a molecule..."
called nitric oxide, which is carried by red blood cells
to the endogenous brown cells and activates those
cells."

If the HUMBLE technique continues to prove out in
pre-clinical research, it might eventually be possible
to generate this type of cell for individual patients,
Tseng suggests. Such a procedure would remove a
tiny amount of a patient's white fat cells, isolate the
progenitor cells, modify those cells to boost
expression of UCP1, and then return the resulting
HUMBLE cells to the patient.

"Employing cell-based or gene therapies to treat
obesity or type 2 diabetes used to be science
fiction," she says. "Now scientific advances, such
as CRISPR gene-editing technologies, will help us
to improve the metabolism, the body weight, the
quality of life and the overall health of people with
obesity and diabetes."

More information: C.-H. Wang et al., "CRISPR-
enabled human brown-like adipocytes prevent
diet-induced obesity and ameliorate metabolic
syndrome in mice," Science Translational Medicine
(2020). [stm.sciencemag.org/lookup/doi/...]

However, that individualized approach would be
complicated and expensive, so the Tseng lab is
pursuing two alternative routes that may be more
practical for clinical use.

One alternative is to use cells that are not
personalized but instead are encapsulated via
biomaterials that protect the cells from rejection by
a patient's immune system. (Joslin researchers and
their collaborators have long studied such materials
for cell transplants for type 1 diabetes.) The other
option is gene therapies that directly express the
UCP1 gene in white fat progenitor cells in the body,
so that those cells acquire HUMBLE-like properties.

Tseng emphasizes that this research is moving
ahead despite the COVID-19 pandemic, which puts
people with diabetes at much higher risk of serious
outcomes if they are infected.